Safety of diphtheria, tetanus, acellular pertussis and inactivated poliovirus (DTaP-IPV) vaccine

Vaccine

Volumn 32, Issue 25, 2014, Pages 3019-3024

  Daley, Matthew F ^a,b   Yih, W Katherine ^c   Glanz, Jason M ^a   Hambidge, Simon J ^a,b,d   Narwaney, Komal J ^a   Yin, Ruihua ^c   Li, Lingling ^c   Nelson, Jennifer C ^e,f   Nordin, James D ^g   Klein, Nicola P ^h   Jacobsen, Steven J ⁱ   Weintraub, Eric ^j  

^a Kaiser Permanente Colorado   (United States)

^b Children's Hospital Colorado   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d DENVER HEALTH   (United States)

^e GROUP HEALTH RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g HEALTHPARTNERS INSTITUTE   (United States)

^h DIVISION OF RESEARCH   (United States)

ⁱ Department of Research and Evaluation Kaiser Permanente Southern California ^*  (United States)

^j CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

more..

Author keywords

Acellular pertussis; Diphtheria; Immunization; Inactivated poliovirus combined vaccine; Surveillance; Tetanus; Vaccine; Vaccine safety

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE;

ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTICLE; CEREBROVASCULAR ACCIDENT; CHILD; CONTROLLED STUDY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG SAFETY; ELECTRONIC MEDICAL RECORD; EMERGENCY WARD; ENCEPHALITIS; GUILLAIN BARRE SYNDROME; HUMAN; ICD-9-CM; INCIDENCE; MAJOR CLINICAL STUDY; MENINGITIS; MYELITIS; PRIORITY JOURNAL; SEIZURE; STEVENS JOHNSON SYNDROME; VACCINATION;

ACELLULAR PERTUSSIS; DIPHTHERIA; IMMUNIZATION; INACTIVATED POLIOVIRUS COMBINED VACCINE; SURVEILLANCE; TETANUS; VACCINE; VACCINE SAFETY;

ADVERSE DRUG REACTION REPORTING SYSTEMS; CHILD; CHILD, PRESCHOOL; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; ELECTRONIC HEALTH RECORDS; HUMANS; POLIOVIRUS VACCINE, INACTIVATED; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; UNITED STATES; VACCINES, COMBINED;

EID: 84899954400     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.03.063     Document Type: Article

References (38)

1. Centers for Disease Control and Prevention Recommended immunization schedules for persons aged 0 through 18 Years-United States, 2012. MMWR Morb Mortal Wkly Rep 2012, 61(5):1-4.
2. Centers for Disease Control and Prevention Licensure of a diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine and guidance for use as a booster dose. MMWR Morb Mortal Wkly Rep 2008, 57(39):1078-1079.
3. Black S., Friedland L.R., Schuind A., Howe B. Immunogenicity and safety of a combined DTaP-IPV vaccine compared with separate DTaP and IPV vaccines when administered as pre-school booster doses with a second dose of MMR vaccine to healthy children aged 4-6 years. Vaccine 2006, 24(35-36):6163-6171.
4. Marshall H., Nolan T., Roberton D., et al. A comparison of booster immunisation with a combination DTPa-IPV vaccine or DTPa plus IPV in separate injections when co-administered with MMR, at age 4-6 years. Vaccine 2006, 24(35-36):6120-6128.
5. Black S., Friedland L.R., Ensor K., Weston W.M., Howe B., Klein N.P. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age. Pediatr Infect Dis J 2008, 27(4):341-346.
6. GlaxoSmithKline Biologicals Full prescribing information, Kinrix (Kinrix package insert) GlaxoSmithKline Biologicals. Research Park Triangle, NC, Package insert date July 2012.
7. Omer S.B., Salmon D.A., Orenstein W.A., deHart M.P., Halsey N. Vaccine refusal, mandatory immunization, and the risks of vaccine-preventable diseases. N Engl J Med 2009, 360(19):1981-1988.
8. Chatterjee A., O'Keefe C. Current controversies in the USA regarding vaccine safety. Expert Rev Vaccines 2010, 9(5):497-502.
9. Lieu T.A., Kulldorff M., Davis R.L., et al. Real-time vaccine safety surveillance for the early detection of adverse events. Med Care 2007, 45(10 Supl 2):S89-S95.
10. Yih W.K., Kulldorff M., Fireman B.H., et al. Active surveillance for adverse events: the experience of the Vaccine Safety Datalink project. Pediatrics 2011, 127(Suppl 1):S54-S64.
11. Baggs J., Gee J., Lewis E., et al. The Vaccine Safety Datalink: a model for monitoring immunization safety. Pediatrics 2011, 127(Suppl 1):S45-S53.
12. Kulldorff M., Davis R.L., Kolczak M., Lewis E., Lieu T., Platt R. A maximized sequential probability ratio test for drug and vaccine safety surveillance. Seq Anal 2011, 30(1):58-78.
13. Zhou W., Pool V., Iskander J.K., et al. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)-United States, 1991-2001. MMWR Surveill Summ 2003, 52(1):1-24.
14. Braun M.M., Mootrey G.T., Salive M.E., Chen R.T., Ellenberg S.S. Infant immunization with acellular pertussis vaccines in the United States: assessment of the first two years' data from the Vaccine Adverse Event Reporting System (VAERS). Pediatrics 2000, 106(4):E51.
15. Jackson L.A., Carste B.A., Malais D., Froeschle J. Retrospective population-based assessment of medically attended injection site reactions, seizures, allergic responses and febrile episodes after acellular pertussis vaccine combined with diphtheria and tetanus toxoids. Pediatr Infect Dis J 2002, 21(8):781-786.
16. Barlow W.E., Davis R.L., Glasser J.W., et al. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. N Engl J Med 2001, 345(9):656-661.
17. Pollard J.D., Selby G. Relapsing neuropathy due to tetanus toxoid. Report of a case. J Neurol Sci 1978, 37(1-2):113-125.
18. Stratton K.R., Howe C.J., Johnston R.B. Adverse events associated with childhood vaccines other than pertussis and rubella. Summary of a report from the Institute of Medicine. JAMA 1994, 271(20):1602-1605.
19. Tuttle J., Chen R.T., Rantala H., Cherry J.D., Rhodes P.H., Hadler S. The risk of Guillain-Barre syndrome after tetanus-toxoid-containing vaccines in adults and children in the United States. Am J Public Health 1997, 87(12):2045-2048.
20. Wirrell E., Hill M.D., Jadavji T., Kirton A., Barlow K. Stroke after varicella vaccination. J Pediatr 2004, 145(6):845-847.
21. Chopra A., Drage L.A., Hanson E.M., Touchet N.L. Stevens-Johnson syndrome after immunization with smallpox, anthrax, and tetanus vaccines. Mayo Clin Proc 2004, 79(9):1193-1196.
22. Ball R., Ball L.K., Wise R.P., Braun M.M., Beeler J.A., Salive M.E. Stevens-Johnson syndrome and toxic epidermal necrolysis after vaccination: reports to the Vaccine Adverse Event Reporting System. Pediatr Infect Dis J 2001, 20(2):219-223.
23. Bohlke K., Davis R.L., Marcy S.M., et al. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics 2003, 112:815-820.
24. Yih W.K., Nordin J.D., Kulldorff M., et al. An assessment of the safety of adolescent and adult tetanus-diphtheria-acellular pertussis (Tdap) vaccine, using active surveillance for adverse events in the Vaccine Safety Datalink. Vaccine 2009, 27(32):4257-4262.
25. Gee J., Naleway A., Shui I., et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. Vaccine 2011, 29(46):8279-8284.
26. Nelson J.C., Yu O., Dominguez-Islas C.P., et al. Adapting group sequential methods to observational postlicensure vaccine safety surveillance: results of a pentavalent combination DTaP-IPV-Hib vaccine safety study. Am J Epidemiol 2013, 177(2):131-141.
27. Shui I.M., Shi P., Dutta-Linn M.M., et al. Predictive value of seizure ICD-9 codes for vaccine safety research. Vaccine 2009, 27(39):5307-5312.
28. Mullooly J.P., Donahue J.G., Destefano F., Baggs J., Eriksen E. Predictive value of ICD-9-CM codes used in vaccine safety research. Methods Inf Med 2008, 47(4):328-335.
29. Mullooly J., Drew L., Destefano F., et al. Quality assessments of HMO diagnosis databases used to monitor childhood vaccine safety. Methods Inf Med 2004, 43(2):163-170.
30. Wald A. Sequential tests of statistical hypotheses. Ann Math Stat 1945, 16(2):117-186.
31. Belongia E.A., Irving S.A., Shui I.M., et al. Real-time surveillance to assess risk of intussusception and other adverse events after pentavalent, bovine-derived rotavirus vaccine. Pediatr Infect Dis J 2010, 29(1):1-5.
32. Lee G.M., Greene S.K., Weintraub E.S., et al. H1N1 and seasonal influenza vaccine safety in the vaccine safety datalink project. Am J Prev Med 2011, 41(2):121-128.
33. Li L., Kulldorff M. A conditional maximized sequential probability ratio test for pharmacovigilance. Stat Med 2010, 29(2):284-295.
34. Rowhani-Rahbar A., Klein N.P., Dekker C.L., et al. Biologically plausible and evidence-based risk intervals in immunization safety research. Vaccine 2012, 31(1):271-277.
35. Xu S., Hambidge S.J., McClure D.L., Daley M.F., Glanz J.M. A scan statistic for identifying optimal risk windows in vaccine safety studies using self-controlled case series design. Stat Med 2013.
36. Huang W.T., Gargiullo P.M., Broder K.R., et al. Lack of association between acellular pertussis vaccine and seizures in early childhood. Pediatrics 2010 Jul 19, 126(2).
37. Hauser W.A. The prevalence and incidence of convulsive disorders in children. Epilepsia 1994, 35(Suppl 2):S1-S6.
38. Mullooly J., Drew L., Destefano F., et al. Quality of HMO vaccination databases used to monitor childhood vaccine safety. Vaccine Safety DataLink Team. Am J Epidemiol 1999, 149(2):186-194.